New therapies for castration-resistant prostate cancer: Efficacy and safety

European Urology

Volumn 60, Issue 2, 2011, Pages 279-290

  Beltran, Himisha ^a,k   Beer, Tomasz M ^b   Carducci, Michael A ^c   De Bono, Johann ^d   Gleave, Martin ^e   Hussain, Maha ^f   Kelly, William K ^g   Saad, Fred ^h   Sternberg, Cora ⁱ   Tagawa, Scott T ^a   Tannock, Ian F ^j  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j UNIVERSITY OF TORONTO   (Canada)

^k NONE   (United States)

more..

Author keywords

Abiraterone acetate; AR; Cabazitaxel; Castration resistance; Chemotherapy; Denosumab; Immunotherapy; Novel hormonal therapy; Prostate cancer; Sipuleucel T; Targeted therapy

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CANCER VACCINE; DASATINIB; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; LENALIDOMIDE; MITOXANTRONE; OGX 11; ORTERONEL; PLACEBO; PREDNISONE; PROSTVAC; PROVENGE; SAMARIUM; STEROID; STRONTIUM; TASQUINIMOD; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; IMMUNOTHERAPY; INFECTION; JAW OSTEONECROSIS; KIDNEY FAILURE; LOW DRUG DOSE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHY; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEIZURE; SIDE EFFECT; SKIN DISEASE; THROBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 79959535385     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.04.038     Document Type: Review

References (75)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. V.T. DeVita, T.S. Lawrence, and S.A. Rosenberg DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology ed 9. 2011 Wolters Kluwer Health/Lippincott Williams & Wilkins Philadelphia, PA
3. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
4. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
5. A.J. Armstrong, and D.J. George Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer Prostate Cancer Prostatic Dis 13 2010 108 116
6. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764 (Pubitemid 26185452)
7. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513 (Pubitemid 29368252)
8. S. Sun, C.C. Sprenger, and R.L. Vessella Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
9. K.E. Knudsen, and H.I. Scher Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer Clin Cancer Res 15 2009 4792 4798
10. B. Tetu, J.Y. Ro, A.G. Ayala, D.E. Johnson, C.J. Logothetis, and N.G. Ordonez Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases Cancer 59 1987 1803 1809 (Pubitemid 17075428)
11. J. Picus, S. Halabi, and W.K. Kelly A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006 Cancer 117 2011 526 533
12. W.K. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract] J Clin Oncol 289 Suppl 2010 18s
13. N. Isambert, G. Freyer, S. Zanetta, C. Falandry, K. Soussan Lazard, and P. Fumoleau A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results [abstract] J Clin Oncol 26 Suppl 2008 18s
14. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE) [identifier NCT00519285 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00519285.
15. W.L. Dahut, J.L. Gulley, and P.M. Arlen Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2004 2532 2539 (Pubitemid 41103740)
16. D.P. Petrylak, K. Resto-Garces, M. Tibyan, and S.G. Mohile A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer [abstract 5156] J Clin Oncol 27 2009 15s http://www.asco.org/ ascov2/Meetings/Abstracts?&vmview=abst-detail-view&confID= 65&abstractID=35307
17. Study to evaluate safety and effectiveness of lenalidomide in combination with docetaxel and prednisone for patients with castrate-resistant prostate cancer (Mainsail) [identifier NCT00988208. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00988208.
18. M.A. Carducci, J.B. Nelson, and M.K. Bowling Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics J Clin Oncol 20 2002 2171 2180 (Pubitemid 34408809)
19. M.A. Carducci, F. Saad, and P.A. Abrahamsson A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 110 2007 1959 1966 (Pubitemid 350036854)
20. J.B. Nelson, W. Love, and J.L. Chin Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 2008 2478 2487
21. Docetaxel and prednisone with or without atrasentan in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy [identifier NCT00134056 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00134056.
22. N.D. James, A. Caty, and H. Payne Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial BJU Int 106 2010 966 973
23. A phase III trial of ZD4054 (zibotentan) (endothelin A antagonist) and docetaxel in metastatic hormone resistant prostate cancer (ENTHUSE M1C) [identifier NCT00617669 ]. ClinicalTrials.gov Web site. http://clinicaltrials. gov/ct2/show/NCT00617669.
24. J. Araujo, A.J. Armstrong, and E.L. Braud Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086) [abstract] J Clin Oncol 27 Suppl 2009 15s
25. Randomized study comparing docetaxel plus dasatinib to docetaxel plus placebo in castration-resistant prostate cancer [identifier NCT00744497 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00744497.
26. K.N. Chi, S.J. Hotte, and E. Yu National Cancer Institute of Canada-Clinical Trials Group. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) [abstract] J Clin Oncol 25 Suppl 2007 18s
27. Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY) [identifier NCT01188187 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01188187.
28. A study evaluating the clinical benefit of adding custirsen to docetaxel retreatment/prednisone as second line therapy in men with castrate resistant prostate cancer (CRPC) [identifier NCT01083615 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01083615.
29. D.M. Peehl, R.J. Skowronski, G.K. Leung, S.T. Wong, T.A. Stamey, and D. Feldman Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells Cancer Res 54 1994 805 810 (Pubitemid 24068341)
30. T.M. Beer, C.W. Ryan, and P.M. Venner Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators J Clin Oncol 25 2007 669 674 (Pubitemid 350002922)
31. H.I. Scher, J. Xiaoyu, and K. Chi Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer J Clin Oncol 29 2011 2191 2198
32. Y. Loriot, C. Massard, and M. Gross-Goupil The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer Eur J Cancer 46 2010 1770 1772
33. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
34. Kelly WK. Epothilones in prostate cancer. Urol Oncol. In press. DOI:10.1016/j.urolonc.2009.08.005.
35. C.N. Sternberg, D.P. Petrylak, and O. Sartor Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
36. W.K. Oh, M.H. Tay, and J. Huang Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 109 2007 477 486 (Pubitemid 46190955)
37. Carboplatin plus docetaxel (Taxotere) in anaplastic prostate cancer [identifier NCT00514540 ]. ClinicalTrials.gov Web site. http://clinicaltrials. gov/ct2/show/NCT00514540.
38. R. Pili, M. Haggman, and W.M. Stadler A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC) [abstract] J Clin Oncol 28 Suppl 2010 15s
39. A study of tasquinimod in men with metastatic castrate resistant prostate cancer [identifier NCT01234311 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01234311.
40. G. Attard, A.H. Reid, and R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
41. D.C. Danila, M.J. Morris, and J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
42. C.J. Ryan, M.R. Smith, and L. Fong Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 28 2010 1481 1488
43. de Bono JS. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Paper presented at: 35th Annual Congress of the European Society for Medical Oncology; October 8-12, 2010; Milan, Italy.
44. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer [identifier NCT00887198 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00887198.
45. C. Tran, S. Ouk, and N.J. Clegg Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
46. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
47. Safety and efficacy study of MDV3100 in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy (AFFIRM) [identifier NCT00974311 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00974311.
48. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL) [identifier NCT01212991 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/ NCT01212991.
49. R. Dreicer, D.B. Agus, G.R. MacVicar, J. Wang, D. MacLean, and W.M. Stadler Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study [abstract] J Clin Oncol 28 Suppl 2010 15s
50. Study comparing Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer [identifier NCT01193244 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/ NCT01193244.
51. Study comparing Orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer [identifier NCT01193257 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01193257.
52. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
53. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094 (Pubitemid 46638945)
54. C.S. Higano, P.F. Schellhammer, and E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
55. P.W. Kantoff, T.J. Schuetz, and B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
56. E. Small, N. Sacks, and J. Nemunaitis Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer Clin Cancer Res 13 2007 3883 3891 (Pubitemid 47037595)
57. C. Higano, J. Corman, and D. Smith Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer Cancer 113 2008 975 984
58. Tollefson MK, Karnes RJ, Thompson RH, et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [abstract 168]. Abstract presented at: American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA. http://www.asco.org/ascov2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=73&abstractID=30897.
59. Phase 3 study of immunotherapy to treat advanced prostate cancer [identifier NCT01057810 ]. ClinicalTrials.gov Web site. http://clinicaltrials. gov/ct2/show/NCT01057810.
60. Study of immunotherapy to treat advanced prostate cancer [identifier NCT00861614 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/ NCT00861614.
61. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882 (Pubitemid 38807610)
62. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
63. M.R. Smith, B. Egerdie, and N. Hernandez Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
64. V.J. Lewington, A.J. McEwan, and D.M. Ackery A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone Eur J Cancer 27 1991 954 958
65. A.N. Serafini, S.J. Houston, and I. Resche Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial J Clin Oncol 16 1998 1574 1581 (Pubitemid 28175783)
66. S. Nilsson, L. Franzen, and C. Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594 (Pubitemid 46995621)
67. S. Nilsson, L. Franzén, and C. Tyrrell Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): results from a randomized, placebo-controlled, phase II study [abstract] J Clin Oncol 25 Suppl 2007 18s
68. A phase III study of alpharadin (Radium-223) in patients with symptomatic hormone refractory prostate cancer with skeletal metastases (ALSYMPCA) [identifier NCT00699751 ]. ClinicalTrials.gov Web site. http://clinicaltrials. gov/ct2/show/NCT00699751.
69. S. Halabi, N.J. Vogelzang, S.S. Ou, K. Owzar, L. Archer, and E.J. Small Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer J Clin Oncol 27 2009 2766 2771
70. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
71. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237 (Pubitemid 46606398)
72. D.R. Shaffer, M.A. Leversha, and D.C. Danila Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 2023 2029 (Pubitemid 46649868)
73. G. Attard, J.F. Swennenhuis, and D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
74. S.L. Stott, R.J. Lee, and S. Nagrath Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer Sci Transl Med 2 2010 25ra3
75. J.P. Gleghorn, E.D. Pratt, and D. Denning Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody Lab Chip 10 2010 27 29